News and Trends 9 Feb 2017 Gene Therapy Biotech Founded to Save the CEO’s Daughter Goes Public in France Lysogene has raised €22.6M from its IPO on Euronext Paris that will contribute to the completion of clinical trials to treat the rare genetic diseases. Karen Aiach, CEO of Lysogene, started the company back in 2009 to develop a life-saving treatment for her daughter Ornella with Sanfilippo A. This rare genetic disease severely affects the nervous system of […] February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jan 2017 UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26) billion. The Swiss biotech’s R&D assets will be spun out into a new company that will remain independent. UPDATE (03/01/2017): The deal has veered towards splitting Actelion into two companies, one for its commercialized portfolio […] January 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2017 Shire sells its RNA platform to a US-based Biotech Shire has sold its RNA therapy program to a smaller biotech that wants to accelerate the development of products from the platform. The Irish drug giant Shire is giving its MRT program, which includes two mRNA platforms and 12 employees, to US-based RaNA Therapeutics. In exchange, Shire will receive an undisclosed share of equity in the biotech as well […] January 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 How is Biotech responding to Patient Advocacy in Rare Disease? A panel of experts in rare disease discussed some of the latest trends at Labiotech Refresh, focusing on the growing patient involvement and how it is benefiting this field. Rare diseases are attracting biotech and pharma more and more since they are typically less crowded areas with unmet clinical needs. However, the lower numbers of […] December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 UPDATE: More Good News on a Cannabis Derivative for Epilepsy Update (07/12/2017): GW Pharma has announced more positive Phase III results for Epidiolex, pushing the drug closer to the market and a win for supporters of legalizing marijuana. Originally published on 27/09/2016 GW Pharmaceuticals just released the results of its third successful Phase III clinical trial for Epidiolex (cannabidiol), a drug that can reduce the frequency of […] December 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2016 New British Partnership set to Cure Rare Diseases with Gene Therapy Oxford BioMedica and Orchard Therapeutics are partnering up to bring gene therapy to the market and treat rare diseases for which no cure is available yet. Oxford BioMedica develops lentiviral vectors for gene and cell therapy applications. The company just announced a partnership with another biotech from the UK’s golden triangle, Orchard Therapeutics. The deal is […] November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2016 NHS adopts Next-Gen Sequencing to Test for Birth Defects Despite a lawsuit from Illumina, Premaitha forged ahead with its NGS-based non-invasive prenatal test; the NHS just adopted it as a standard screen. With its seemingly infinite applications, next-generation sequencing (NGS) is a hot area, especially for diagnostics biotechs. A number have been founded in recent years to develop prenatal tests for birth defects, and […] November 2, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email